Form D · Other
TITAN MEDICAL INC
Toronto, A6 · CIK 0000840551
Offering snapshot reported Mar 10, 2021 · SEC filing
- Reported sold
- $3.04M Offering amount: $4.94M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 24, 2021 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 10, 2021 | Amendment | $3,040,800 | $0vs Mar 9, 2021 | 4 | SEC filing |
| Mar 9, 2021 | Initial | $3,040,800 | No comparison | 4 | SEC filing |
| Feb 8, 2021 | Initial | $525,450 | No comparison | 3 | SEC filing |
| May 20, 2020 | Initial | $813,886 | No comparison | 2 | SEC filing |
| Nov 2, 2017 | Initial | $1,860,020 | No comparison | 18 | SEC filing |
| Nov 2, 2017 | Initial | $325,000 | No comparison | 6 | SEC filing |
| May 1, 2014 | Initial | $1,269,061 | No comparison | 1 | SEC filing |
| Mar 28, 2012 | Initial | $2,119,740 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $213K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-391584
Total remaining to be sold represents maximum potential exercise price of warrants.
Unit offering; each Unit consists of one common share and one-half of one common share purchase warrant; each whole warrant exercisable at $3.00 for 24 months.
In addition to the cash compensation above, the agents received 88,690 warrants in connection with certain U.S. sales; each warrant is exercisable for one share of common stock at $3.00 for 24 months.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Bloom Burton Securities Inc. | None | Haywood Securities (USA) Inc. · CRD 42072 |
Source: Form D, filed Mar 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John E. Barker | Director |
| Martin Bernholtz | Director |
| Paul Cataford | Director |
| Monique L. Delorme | Executive |
| Monique L. Delorme | Executive |
| Charles Federico | Director |
| Anthony J. Giovinazzo | Director |
| Anthony J. Giovinazzo | Director |
| John T. Hargrove | Director, Executive |
| Craig Leon | Director, Executive |
| David Mc Nally | Director, Executive |
| Stephen Randall | Director |
| Reiza Rayman | Director, Executive |
| John E. Schellhorn | Director |
| Joseph Talarico | Executive |
| John R. Valvo | Executive |
| Cary G. Vance | Director |
| Cary G. Vance | Director |
| Bruce Wolff | Director |
Issuer details
Industry: Other (See others in industry)
Address:Toronto, A6, M5H 3B7